Lipoproteins and other Risk Factors for Cardiovascular Disease in a Student Population

Open access


Background: Cardiovascular disease (CVD) is a major cause of mortality and morbidity in many populations, especially in developed countries. The aim of the study was to analyze the lipid status in a student population at increased risk for CVD in comparison with students who are not at increased risk for CVD.

Methods: This study included 238 students from the University of Novi Sad of both sexes (126 men and 112 women), with a mean age of 22.32±1.85 years. According to the body mass index (BMI) lower and higher than 25 kg/m2 and waist circumference (WC) of less and more than 94 cm (80 cm for females) the whole group of 238 students was divided into 2 subgroups: the group at increased risk for CVD (Group 1) and the group at lower risk for CVD (Group 2). Total cholesterol - TCH, triglycerides - TG, high density lipoprotein cholesterol - HDL-c, low density lipoprotein cholesterol - LDL-c, very low-density lipoprotein cholesterol - VLDL-c concentrations were determined and the index of atherosclerosis (IA), established risk factors RF-TCH/HDL-c ratio and non-HDL-c/HDL-c ratio were mathematically calculated.

Results: The values of TCH, LDL-c, non-HDL-c, VLDL-c and TG were significantly higher in Group 1 compared to Group 2 (P<0.001). IA, non-HDL-c/HDL-c and RF-TCH/HDL-c ratio were also significantly higher (P<0.001), while HDL-c was significantly lower (p<0.01) in Group 1 compared to controls. These results were not influenced by gender in both groups of subjects.

Conclusions: The data suggest that increased anthropometric parameters are followed by increased lipoprotein status in the group of students at increased risk for CVD and screening of the lipid status is necessary in students, especially in those who are at increased risk for CVD.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Niskanen A Saramaki M Schwandt E. Myeloperoxidase (MPO) and hs-CRP as predictive factors for myocardial infarction. CLI-Clin Lab Int 2006; 30(7): 38-9.

  • 2. Ali AA Phalisteen S El-Napolis M Fahmy MA. Lipo-protein metabolism abnormalities in patients with chronic renal insufficiency. Journal of Medical Biochemistry 2011; 30: 38-44.

  • 3. Gruson D. Time is muscle. Lab Med Int 2006; 23(3): 4.

  • 4. Berenson SG Srinivasan RS Bao W et al. Association between Multiple Cardiovascular Risk Factors and Athe - rosclerosis in Children and Young Adults. NEJM 1998; 338: 1650-6.

  • 5. Veigas NM Dharmalingam M Rani Marcus S. Oxidative stress in obesity and metabolic syndrome in Asian Indians. Journal of Medical Biochemistry 2011; 30: 115-20.

  • 6. Palinski W Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to athe - rogenesis. The FASEB Journal 2002; 16: 1348-60.

  • 7. De Backer G Ambrosioni E Borch-Johensen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint Task Force of Euro - pean and other Societies on Cardiovascular Disease Pre - vention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.

  • 8. Đerić M Čabarkapa VS. Cardiovascular biomarkers in chronic kidney disease. Journal of Medical Biochemistry 2010; 29: 298-303.

  • 9. Howie-Esquivel J White M. Biomarkers in acute cardio vas - cular disease. J Cardiovasc Nurs 2008; 23(2): 124-31.

  • 10. Keller T Tzikas S Zeller T Czyz E Lillpopp L Ojeda FM et al. Copeptin improves early diagnosis of acute myo car dial infarction. J Am Coll Cardiol 2010; 55: 2096-106.

  • 11. Enhörning S Wang TJ Nilsson PM Almgren P Hedblad B Berglund G et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 121: 2102-8.

  • 12. Wollert KC. GDF-15 for risk stratification and therapeutic guidance in acute coronary syndrome. Clin Lab Int 2011; 35: 34-7.

  • 13. Shovakumar N Kumar MJ Aswathanarayan MN Venkatesh MS Sheshadri M Deshmukh S et al. Role of retinol-binding protein 4 in obese Asian Indians with meta bolic syndrome. Journal of Medical Biochemistry 2012; 31(1): 40-6.

  • 14. Erqou S Kaptoge S Perry PL Di Angelantonio E Thompson A et al. Lipo protein(a) concentration and the risk of coronary heart disease stroke and nonvascular mortality. The Emerging Risk Factors Collaboration. JAMA 2009; 302: 412-23.

  • 15. Friedewald WT Levy RI Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

  • 16. The Expert panel. The third report of the National Education Program (NCEP) Expert Panel on detection evaluation and treatment of high blood cholesterol in Adults (Adult treatment panel III). Final report. Circulation 2002; 106: 3143-421.

  • 17. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.

  • 18. Keating MT Sanguinetti MC. Molecular genetic insight into cardiovascular disease. Science 1996; 272: 681-5.

  • 19. Khera Amit V Cuchel MD De la Liera-Moya M Ro d - rigues A Burke MF Jafri K et al. Cholestrol efflux capacity high-density lipoprotein function and atherosclerosis. N Engl J Med 2011; 364: 127-35.

  • 20. Gordon DJ Rifkind BM. High density lipoprotein: the cli - nical implications of recent studies. N Engl J Med 1989; 321: 1311-12.

  • 21. Hill SA McQueen MJ. Reverse cholesterol transport - a review of the process and its clinical implications. Clin Biochem 1997; 30: 517-20.

  • 22. Stevens RJ Kothari V Adler AI Stratton IM Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001; 101: 617-19.

  • 23. Rothblat GH Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21(3): 229-38.

  • 24. Chan RSM Woo J. Prevention of Overweight and Obe - sity: How effective is the current Public Health Approach. Int J Environ Res Public Health 2010; 7: 765-83.

  • 25. Bertsias G Mammas I Linardakis M Kafatos A. Over - weight and obesity in relation to cardiovascular disease risk factors among medical students in Crete Greece. BMC Public Health 2003; 3:3.

  • 26. Bertsias G Linardakis M Mammas I Kasfatos A. Fruit and vegetables consumption in relation to health and diet of medical students in Crete Greece. Int J Vitam Nutr Res 2005; 75(2): 107-17.

  • 27. Đorđević BV Jevtović-Stoimenov T Stojanović I Ćosić V. Uloga endotela u aterogenezi. In: Evaluacija dijagnostika i terapija dislipidemija. Medicinski fakultet Ni{ 2003 129-36.

  • 28. Majkić-Singh N. Razvoj biomarkera na principima medicine zasnovane na dokazima. Jug Med Biohem 2005; 24 (Suppl 4): 1-10.

  • 29. Fox K Garcia MA Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27(11): 1341-81.

  • 30. Fourth Joint Task Force of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. EJCPR 2007; vol 14 suppl 2: S1-S113.

  • 31. Mackay J Mensah G. Atlas of Heart Disease and Stroke. Geneva: WHO. 2004.

Journal information
Impact Factor

IMPACT FACTOR 2018: 2.000
5-year IMPACT FACTOR: 1.075

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 259 92 6
PDF Downloads 77 39 1